Summing up: An action plan for ALS research

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue SUPPL. 1, 2004, Pages 141-143

  Rowland, Lewis P ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CREATINE; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN; RILUZOLE; SOMATOMEDIN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL RESEARCH; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG SCREENING; EXPERIMENTAL DESIGN; FAMILIAL DISEASE; GENE THERAPY; HEALTH CENTER; HUMAN; NONHUMAN; ORGANIZATION; PATHOGENESIS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GROUP PROCESSES; HUMANS; RESEARCH; STEM CELL TRANSPLANTATION;

EID: 6444221702     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/17434470410020814     Document Type: Conference Paper

References (4)

1. Clement AM, Nguyen MD, Roberts EA et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302: 113-117.
2. Lu YY, Wang LJ, Muramatsu S et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motor neurons by retrograde transport. Neurosci Res 2003; 45: 33-40.
3. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 30: 839-842.
4. Sung NS, Crowley WF Jr, Genel M et al. Central challenges facing the national clinical research enterprise. JAMA 2003; 12: 1278-1287.